Article

The Latest News and Updates in Kidney Cancer

Author(s):

Ryan McDonald

A roundup of the latest news and updates for patients with Renal Cell Carcinoma from CURE®.

kidney cancer RCC renal cell carcinoma FDA studies news

Known as the most common form of kidney cancer in adults, renal cell carcinoma (RCC) has seen an influx of research in recent weeks. Here, CURE® looks back at some of the latest news and updates in the RCC space.

  • Data presented at the 2020 ASCO Virtual Scientific Meeting demonstrated that MK-6482 appeared to be well tolerated and induced clinical responses among patients with VHL—associated RCC.
  • Updated study results also presented during the 2020 ASCO Virtual Scientific Meeting showed that Keytruda (pembrolizumab) in combination with Inlyta (axitinib) continued to demonstrate significant improvements in progression-free survival (PFS) and overall survival (OS) compared to Sutent (sunitinib) in patients with previously untreated, advanced RCC.
  • A recent feature in CURE®’s Immunotherapy issue highlights how advances in a variety of novel treatments, including immunotherapies, are extending life in patients with advanced kidney cancer.
  • Patients with advanced, previously untreated RCC may soon have a new option in the form of the novel combination of Opdivo (nivolumab) and Cabometyx (cabozantinib), according to study results from the phase 3 CheckMate-9ER trial.
  • The Food and Drug Administration’s recent approval of a higher recommended dose of Keytruda (pembrolizumab) every six weeks for adults across all cancer types, in which the drug is indicated for, is a welcomed change for patients.

For more RCC coverage go here.

Related Videos
CURE spoke with Dr. William C. Huang about what kind of team may be required to treat a patient with metastatic kidney cancer.
Image of man wearing baseball cap backwards.
Dr. Emre Yekedüz highlighted strategies that may improve patients' quality of life and mitigate treatment-related side effects in renal cell carcinoma.
Dr. Guru Sonpavde emphasized the importance of better understanding how genetic mutations influence the treatment of cancer care, particularly GU cancers.
Image of doctor with brown hair.
Image of man with black hair.
.Dr. Catherine Wu, chief of the Division of Stem Cell Transplantation and Cellular Therapies at Dana-Farber Cancer Institute, and institute member at the Broad Institute of MIT and Harvard, in Boston
Dr. Katy Beckermann discusses how a Fotivda and Opdivo combination for renal cell carcinoma compared with Fotivda alone based on patient feedback.
Dr. Catherine Wu is chief of the Division of Stem Cell Transplantation and Cellular Therapies at Dana-Farber Cancer Institute, and institute member at the Broad Institute of MIT and Harvard, in Boston, Massachusetts.
Dr. Alan Tan is the GU Oncology Lead at the Vanderbilt-Ingram Cancer Center in Nashville, Tennessee, as well as an associate professor in the Division of Hematology/Oncology at Vanderbilt University Medical Center and GU Executive Officer with the Alliance for Clinical Trials in Oncology.
Related Content
There were a number of notable developments for patients with kidney cancer at the symposium: © SciePro - stock.adobe.com
March 30th 2025

What Patients With Kidney Cancer Need to Know From ASCO GU

Alex Biese
There were a number of notable developments for patients with kidney cancer at the symposium, Dr. Emre Yekedüz explained.
Image of CURE's Cancer Horizons podcast logo: a white microphone with yellow noise lines. Highlights from the 2024 ASCO gastrointestinal and genitourinary cancer conferences.
January 30th 2024

Highlights from the Gastrointestinal and Genitourinary Cancer Conferences

Alex Biese Brielle Benyon
Here are some of the top stories from the recent Gastrointestinal Cancers Symposium as well as the Genitourinary Cancers Symposium.
March is Kidney Cancer Awareness Month, and voices like Sid Sadler are raising awareness: © Axel Kock - stock.adobe.com
March 27th 2025

Kidney Cancer Awareness Month Highlights Advocacy and Early Detection

Ryan Scott
March is Kidney Cancer Awareness Month, highlighting the disease, early detection and and patient advocacy, with voices like Sid Sadler raising awareness.
cancer horizons podcast logo
December 20th 2023

FDA Approves 3 Treatments, Cancer Vaccine Shows Promise

Alex Biese Brielle Benyon
The Food and Drug Administration recently approved treatment for some patients with neuroblastoma, kidney cancer and bladder cancer. Elsewhere, a cancer vaccine made headlines for the treatment of patients with melanoma.
Among patients with RCC, those with larger tumors may yield benefit from SBRT: © vitanovski - SciePro.
March 17th 2025

SBRT May Offer Best Control Rates for Larger RCC Tumors, Study Finds

Ryan Scott
Among patients with renal cell carcinoma, those with larger tumors may yield the most benefit from SBRT compared with other ablative options.
Dr. Chandler Park helps patients with genitourinary cancer understand the importance of genetic testing: © lucky - stock.adobe.com
February 28th 2025

There is a Growing Need For Genetic Testing and Precision Medicine in GU Cancers

Ryan Scott
Dr. Chandler Park helps patients with genitourinary cancers, including both prostate and bladder, understand the importance of genetic testing.